Harbour BioMed and Kelun Biotech License TSLP Monoclonal Antibody to Windward Bio
CompanyDeals

Harbour BioMed and Kelun Biotech License TSLP Monoclonal Antibody to Windward Bio

Hengrui's Recaticimab Approved for Hypercholesterolemia Treatment
CompanyDrug

Hengrui’s Recaticimab Approved for Hypercholesterolemia Treatment

HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics
CompanyDeals

HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics

Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1819 Phase II Study
CompanyDrug

Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1819 Phase II Study

Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4375 Clinical Trial
CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4375 Clinical Trial

Ouro Medicines Launches with $120M Series A Financing for CM336 Development
CompanyDeals

Ouro Medicines Launches with $120M Series A Financing for CM336 Development

Menarini Group Expands Oncology Pipeline with Insilico Medicine License
CompanyDeals

Menarini Group Expands Oncology Pipeline with Insilico Medicine License

Zai Lab Secures Rights to Vertex's Povetacicept in Key Asian Markets
CompanyDeals

Zai Lab Secures Rights to Vertex’s Povetacicept in Key Asian Markets

Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion
CompanyDeals

Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion

Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development
CompanyDeals

Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development

Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market
CompanyDeals

Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market

Sepax Technologies Debuts on STAR Market with Soaring IPO Prices
CompanyDeals

Sepax Technologies Debuts on STAR Market with Soaring IPO Prices